Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -49,591 | -57,532 | -9,986 | 17,888 | -56,693 |
| Depreciation Amortization | 53 | 10 | 6 | 4 | 4 |
| Accounts receivable | 1,568 | -2,637 | 372 | -1,298 | N/A |
| Accounts payable and accrued liabilities | 7 | 220 | 1,082 | -515 | 381 |
| Other Working Capital | -2,154 | 3,090 | 4,076 | -5,555 | 181 |
| Other Operating Activity | 14,864 | 31,273 | 3,338 | 3,790 | 36,757 |
| Operating Cash Flow | $-35,253 | $-25,576 | $-1,112 | $14,314 | $-19,370 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | -100 |
| Net Acquisitions | N/A | 1,210 | N/A | N/A | N/A |
| Investing Cash Flow | $N/A | $1,210 | $N/A | $N/A | $-100 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 646 |
| Debt Issued | 1,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 49,175 | 4,265 | 8,979 | 4,455 | 28,578 |
| Common Stock Repurchased | -152 | -79 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | -669 | -1,619 |
| Financing Cash Flow | $50,023 | $4,186 | $8,979 | $3,786 | $27,605 |
| Beginning Cash Position | 30,321 | 50,501 | 42,634 | 24,534 | 16,399 |
| End Cash Position | 45,091 | 30,321 | 50,501 | 42,634 | 24,534 |
| Net Cash Flow | $14,770 | $-20,180 | $7,867 | $18,100 | $8,135 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,253 | -25,576 | -1,112 | 14,314 | -19,370 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -100 |
| Free Cash Flow | -35,253 | -25,576 | -1,112 | 14,314 | -19,470 |